
	Where results make sense

Topic: Takeda Pharmaceuticals

Related Topics

Lists of companies

Novo Nordisk

AstraZeneca

List of pharmaceutical companies

Abbott Laboratories

GlaxoSmithKline

Akzo Nobel

Amgen

In the News (Fri 17 Feb 12)

EXECUTIVE POWER

Iran

ANALYSIS

Pakistan

Family compact

	Takeda - Wikipedia, the free encyclopedia
		Takeda Shingen, one of the most famous daimyō in Japanese history.
		Takeda family, the family of Takeda Shingen, and a relatively important and powerful one therefore, in Japan's Sengoku period.
		Takeda is a PC video game based on the life of Takeda Shingen, developed by Magitech Corporation.
	en.wikipedia.org /wiki/Takeda (136 words)

	Type 2 Diabetes and Insulin Resistance (Site not responding. Last check: 2007-10-15)
		Takeda Pharmaceuticals North America, Inc., and Eli Lilly and Company entered into an agreement to co-promote ACTOS tablets for the treatment of type 2 diabetes in the United States.
		Takeda is internationally recognized as a leader in research and development, focusing on treatments for diabetes; cardiovascular and allergic disease; bone, joint, and central nervous system disorders; and atherosclerosis.
		Takeda Pharmaceuticals North America, Inc. is an independent, wholly-owned subsidiary of Takeda Chemical Industries, Ltd. The alliance with Lilly marks the company's entry into the US market for diabetes treatment.
	www.actos.com /sub_sec1_about_tak.asp (377 words)

	Takeda
		Takeda Awards The annual Takeda Awards were presented in 2002 by the Takeda Foundation.
		Takeda Katsuyori Takeda Katsuyori (Takeda Shingen and father of Takeda Nobukatsu.
		Takeda Shingen Takeda Shingen (武田信玄) (Sengoku or "warring states" period.
	www.brainyencyclopedia.com /topics/takeda.html (69 words)

	[No title]
		Takeda’s announced goal was to build the skills needed to launch an independent U.S. drug development effort, thus opening the largest market in the world to their drugs.
		Takeda America continued the trials and established that Actos was efficacious, but only after a period of at least one month and at a much higher dose.
		Takeda received the education they had desired and, as a result, were able to establish an independent presence in the United States.
	faculty.fuqua.duke.edu /~willm/Classes/ccmba2002/TAP.doc (5034 words)

	3M Pharmaceuticals - Takeda news release
		Takeda Pharmaceutical Company Limited is a research-based global company with its main focus on pharmaceuticals.
		As the largest pharmaceutical company in Japan and one of the industry’s leaders worldwide, Takeda is committed to strive toward better health for individuals and progress in medicine by developing superior pharmaceutical products.
		Takeda is actively dedicated to enhance its pipeline for future growth through alliance as well as in-house R&D activities.
	www.3m.com /us/healthcare/pharma/Takeda.jhtml (829 words)

	Indevus Pharmaceuticals - Current News (Site not responding. Last check: 2007-10-15)
		Takeda would be responsible for funding future Phase 4 studies of CerAxon in stroke and, in the future, Phase 3 studies for additional indications.
		Takeda intends to directly commercialize CerAxon through Takeda Pharmaceuticals America, Inc., established in 1998 as the wholly owned U.S. marketing subsidiary of Takeda Chemical Industries, Ltd. Takeda Pharmaceuticals America co-promotes Actos (pioglitazone hydrochloride) with Eli Lilly and Company in the U.S. diabetes market.
		Takeda Chemical Industries, Ltd. is an R and D-oriented corporation specializing in pharmaceuticals and is the largest pharmaceutical company in Japan.
	www.interneuron.com /news/12_02_99.html (660 words)

	Takeda Alliance with BioNumerik to Market Tavocept, Phase III Chemoprotective Agent, in US/Canada
		Takeda President and COO Yasuchika Hasegawa stated, "We are extremely excited to enter into an alliance agreement with BioNumerik for Tavocept.
		Takeda's U.S. based global research and development organization, Takeda Global Research & Development Center Inc., submitted a new drug application (NDA) to the FDA to market ramelteon (TAK-375), its investigational drug for insomnia on September 22, 2004.
		Takeda is a research-based global company with its main focus on pharmaceuticals.
	www.medicalnewstoday.com /medicalnews.php?newsid=14673 (915 words)

	Insomnia - FDA approved ROZEREM (ramelteon) (Site not responding. Last check: 2007-10-15)
		Takeda Pharmaceuticals North America, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for ROZEREMTM (ramelteon) 8-mg tablets for the treatment of insomnia characterized by difficulty with sleep onset.
		Based in Lincolnshire, Ill., Takeda Pharmaceuticals North America, Inc. is a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, the largest pharmaceutical company in Japan.
		Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products.
	www.medicalnewstoday.com /medicalnews.php?newsid=27882 (889 words)

	American Heart Association (Site not responding. Last check: 2007-10-15)
		Takeda Chemical Industries was founded over two centuries ago and is Japan's largest pharmaceutical company.
		With more than 16,000 employees worldwide, Takeda is internationally recognized as a leader in research and development, focusing on treatments for diabetes, cardiovascular and allergic disease, bone and joint and central nervous system disorders.
		Established in 1998, Takeda Pharmaceuticals North America's mission is to supply quality, innovative products along with services to meet the needs of the health care community and to provide a better life for the patients we serve.
	www.s2mw.com /hod/sponsors.html (349 words)

	PharmiWeb: Press Release: Takeda Pharmaceuticals North America, Inc., Supports the American Psychiatric Foundation with ... (Site not responding. Last check: 2007-10-15)
		“Takeda believes in the mission of the American Psychiatric Foundation and is proud to support the foundation’s matching gift program,” said Takeda Neuroscience Medical Director Louis Mini, M.D., a board certified adult and geriatric psychiatrist and APA member.
		Contributions to the foundation’s annual fund are used to support education and research programs that promote early recognition of mental illnesses, increase access to quality mental health services, and enhance treatment outcomes.
		Takeda is a research-based global pharmaceutical company developing compounds for central nervous system conditions, diabetes, sleep, cardiovascular disease and other conditions.
	www.pharmaceuticaljobs.co.uk /pressreleases/pressrel.asp?ROW_ID=826 (350 words)

	FDA Warning Letter, Takeda Pharmaceuticals North America, Inc. (Actos (pioglitazone hydrochloride) Tablets)
		Specifically, a new Warnings section was added to address concerns about fluid retention, which may contribute to heart failure, with particular concern when Actos is used in combination with insulin: In addition, the Precautions and Adverse Reactions sections were revised with respect to cardiac effects of Actos monotherapy and combination therapy, weight gain, and edema.
		Takeda should immediately cease distribution and publication of these Sales Aids, and all other promotional materials for Actos that omit important safety information and that contain the same or similar claims or presentations.
		In its letter to DDMAC, Takeda should include a list of all promotional materials that were discontinued, and the discontinuation date.
	www.pharmcast.com /WarningLetters/Yr2002/November2002/Takeda1102.htm (977 words)

	PharmaDeals E-News (Site not responding. Last check: 2007-10-15)
		Sucampo Pharmaceuticals and Takeda Pharmaceutical have entered into a collaboration and licence agreement for lubiprostone, which was developed by Sucampo in the US as a novel compound with a new mechanism of action for the treatment of chronic constipation and constipation-predominant irritable bowel syndrome (IBS).
		Takeda's wholly owned US subsidiary, Takeda Pharmaceuticals North America, will sell this product once the product is approved by the US FDA.
		Takeda and Sucampo also agreed on the exclusive manufacturing and supply of lubiprostone by R-Tech Ueno, a member of Sucampo Group.
	www.worldpharmaweb.com /enews/feature0411_3.html (289 words)

	BioSpace News for
		Takeda America Research & Development Center, Inc. announced today that as part of its corporate strategy it would be transferring its pharmaceutical research and development operations in Princeton, New Jersey to its Lincolnshire, Illinois affiliate, Takeda Pharmaceuticals America, Inc. The target date of the merger is the end of December 2000.
		ACTOS® (pioglitazone hydrochloride), which is distributed by Takeda Pharmaceuticals America, Inc. and co-promoted with Eli Lilly and Company, has been the leading thiazolidinedione (TZD) for new prescriptions written by endocrinologists since February 25, 2000, according to IMS Health data.
		Takeda Pharmaceuticals America, Inc., distributor of ACTOS®(pioglitazone hydrochloride), and Eli Lilly and Company are providing continuity of care for patients with type 2 diabetes now searching for therapy alternatives in light of the recent withdrawal of Rezulin®(troglitazone) from the U.S. market.
	www.biospace.com /news_company.cfm?CompanyID=2748&SR=61 (918 words)

	Takeda submits new drug application for combination type 2 diabetes medication
		LINCOLNSHIRE, Ill., June 30, 2005 — Takeda Pharmaceuticals North America today announced that the company has submitted a New Drug Application (NDA) for a new oral medication that combines pioglitazone HCl and glimepiride, a sulfonylurea, to the United States Food and Drug Administration (FDA) for the treatment of type 2 diabetes.
		Takeda submitted a separate NDA for a combination of pioglitazone HCl and metformin HCl in October 2004.
		ACTOS is a registered trademark of Takeda Pharmaceutical Company, Limited and used under license by Takeda Pharmaceuticals North America, Inc.
	www.eurekalert.org /pub_releases/2005-06/k-tsn062905.php (652 words)

	Phase III clinical program evaluates lubiprostone
		BETHESDA, MD — May 16, 2005 — Takeda Pharmaceuticals North America (TPNA) and Sucampo Pharmaceuticals announced the initiation of a phase III clinical development program for lubiprostone in patients with constipation-predominant irritable bowel syndrome (IBS-C).
		Lubiprostone is an investigational compound currently being evaluated by the FDA for the treatment of chronic idiopathic constipation and associated pain and bloating in adults.
		Sucampo Pharmaceuticals, Inc. is a pharmaceutical company that concentrates on developing compounds from its proprietary functional fatty acid technology platform, which consists of exclusive rights in the Americas to a portfolio of more than 650 patents.
	www.eurekalert.org /pub_releases/2005-05/k-pic051605.php (716 words)

	Pharmalicensing.com: : Kos and Takeda multi-year co-promotion agreement
		Kos Pharmaceuticals, Inc and Takeda Pharmaceuticals North America, Inc have signed a three-year agreement to co- promote Kos' Niaspan(r) (extended-release niacin) and Advicor(r) (extended-release niacin/lovastatin) in the United States.
		Kos Pharmaceuticals is a fully integrated specialty pharmaceutical company engaged in developing, commercializing, manufacturing and marketing proprietary prescription products for the treatment of chronic diseases.
		Takeda Pharmaceuticals North America is a wholly owned subsidiary of Takeda Chemical Industries, Ltd. in Osaka, Japan.
	www.pharmalicensing.com /news/headlines/1067962877_3fa7d1fe024f9 (272 words)

	Business Facilities - Corporate Moves: Illinois (Site not responding. Last check: 2007-10-15)
		In April, Governor Rod Blagojevich announced the awarding of more than $15 million in Opportunity Returns support to Takeda Pharmaceuticals North America, Inc. Opportunity Returns is a regional economic development strategy that divides the state into 10 regions—each with a regional team that is empowered and expected to rapidly respond to opportunities and challenges.
		The addition of Takeda's new campus also will serve as another vital component of an emerging biotech corridor taking shape in Northeast Illinois, strengthening the prominence of the industry in the state and attracting new investment to the area.
		The Takeda property consists of 70.4 acres in Deerfield purchased in December 2002.
	businessfacilities.com /bf_05_06_move.asp (1284 words)

	Newswise
		Takeda Pharmaceuticals North America and Sucampo Pharmaceuticals announced the initiation of a phase III clinical development program for lubiprostone in patients with constipation-predominant irritable bowel syndrome.
		Newswise — Takeda Pharmaceuticals North America (TPNA) and Sucampo Pharmaceuticals announced the initiation of a phase III clinical development program for lubiprostone in patients with constipation-predominant irritable bowel syndrome (IBS-C).
		Through the Takeda Global Research and Development Center, Inc., the company has a robust pipeline with compounds in development for diabetes, sleep, cardiovascular disease and other conditions.
	www.newswise.com /articles/view/511861 (738 words)

	Takeda Pharmaceuticals Rebecca - Takeda Pharmaceuticals Rebecca Smith Reviews
		Takeda Pharmaceuticals Rebecca - In the 21st century there are hundreds of pharmaceutical companies in operation around the world.
		Scientists at TPNA’s parent company, Takeda Pharmaceutical Company Limited, were leaders in the discovery of the TZD molecule and have been instrumental in advancing the class.
		Not a day goes by when some news organization is not broadcasting or carrying a report or feature story in which the pharmaceutical industry is not minced and maimed.
	users.tpg.com.au /pharma_/103.htm (3727 words)

	Newcastle Limited - Commercial real estate - Chicago (Site not responding. Last check: 2007-10-15)
		CHICAGO – Lincolnshire, IL-based Takeda Pharmaceuticals North America, Inc., has acquired a 70-acre prime development site in Lake County from Deerfield, IL-based Baxter International Inc. (NYSE: BAX) for a new corporate headquarters campus.
		Takeda made a straightforward offer that achieved all of Baxter’s objectives,” said Michael R. Haney, President of Newcastle.
		Takeda Pharmaceuticals North America, Inc., was founded in 1998 and is a wholly owned subsidiary of Takeda Chemical Industries, Japan’s largest pharmaceutical company.
	www.newcastlelimited.com /jan_2_2003.html (330 words)

	GCIG
		PAUL, Minn. & OSAKA, Japan--(BUSINESS WIRE)--March 1, 2005--3M and Takeda Pharmaceutical Company Limited (Takeda) announced today that the two companies entered into an exclusive co-development and joint marketing agreement to collaborate on a potential topical treatment for cervical high-risk human papillomavirus (HPV) infection and cervical dysplasia.
		HPV can infect the skin surface in any part of the body and is one of the most common sexually transmitted viruses(1).
		About 3M Pharmaceuticals -- Part of the 3M Health Care Family 3M Health Care, the largest of seven major 3M businesses, is dedicated to improving the practice, delivery and outcome of care in medical, dental, pharmaceutical, health information and personal care markets.
	ctep.info.nih.gov /resources/gcig/news030105.html (987 words)

	Building a nationwide marketing firm in just one year
		Diane Ulrich, assistant to Takeda Pharmaceuticals America President Saburo Hamanaka, was the fifth employee to join Takeda in 1998.
		During her first few months on the job Takeda moved three times, as it awaited construction of a new five story high rise in Lincolnshire.
		Takeda was searching for just the right technology to meet a number of specific needs: appropriately outfitting permanent spaces like the executive boardroom and employee training rooms, as well as selecting portable equipment that would allow a travelling sales force to make high-quality presentations on the road.
	www.unitedvisual.com /2train/2tr106.asp (872 words)

	Current Opportunities (Site not responding. Last check: 2007-10-15)
		At Takeda Pharmaceuticals North America, Inc. (TPNA) we're building a different kind of pharmaceutical company, a world-class pharmaceutical company.
		Since our inception in 1998, TPNA has strived to become a world-class pharmaceutical company by supplying quality, innovative products and services to meet the needs of the healthcare community and the patients it serves.
		Takeda Pharmaceuticals North America is a wholly owned subsidiary of Takeda Chemical Industries, Ltd. Takeda Chemical Industries is a research-based global company with its main focus on pharmaceuticals.
	www.medzilla.com /abouttakeda.html (369 words)

	FDA Approved ROZEREM(TM) (ramelteon), First and Only Non-Scheduled Prescription Sleep Medication : ArriveNet Press ... (Site not responding. Last check: 2007-10-15)
		LINCOLNSHIRE, IL -- (Market Wire - Jul 22, 2005) -- Takeda Pharmaceuticals North America, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for ROZEREM(TM) (ramelteon) 8-mg tablets for the treatment of insomnia characterized by difficulty with sleep onset.
		The ROZEREM NDA, submitted in September 2004 by Takeda Global Research and Development Center, Inc., was based on data collected from an extensive clinical research program, including recently completed clinical studies with more than 4,200 patients ages 18 to 93.
		In the United States, Takeda currently markets oral diabetes, insomnia, and cholesterol-lowering treatments, and through the Takeda Global Research and Development Center, Inc., the company has a robust pipeline with compounds in development for diabetes, cardiovascular disease, and other conditions.
	press.arrivenet.com /hea/article.php/673069.html (972 words)

	American Diabetes Association, Takeda Pharmaceuticals North America Launch Second Year of Diabetes Research Program
		"We are proud to support these investigators with the help of Takeda in the advancement of their research and their desire to decrease the number of people living with type 2 diabetes.
		Takeda representatives recognized these scholars and their mentors at the American Diabetes Association Scientific Sessions in Orlando, Fla., on June 4.
		About Takeda Pharmaceuticals North America Based in Lincolnshire, Ill., Takeda Pharmaceuticals North America, Inc. is a wholly owned subsidiary of Takeda Chemical Industries, Ltd. in Osaka, Japan and the marketer of ACTOS, an oral therapy for type 2 diabetes.
	www.prnewswire.com /cgi-bin/stories.pl?ACCT=104&STORY=/www/story/06-04-2004/0002187369&EDATE= (593 words)

	BioPharmaLink profile of Takeda Chemical Industries, Japan,
		It is the largest pharmaceutical company in Japan and among the leaders in the world.
		Takeda discovers, develops, manufactures and markets a broad range of innovative products to improve the health and quality of life of people around the world.
		Takeda has an international marketing network including Japan and 14 overseas bases in the U.S., Europe and Asia.
	biopharmalink.com /companies/1509.htm (330 words)

	HINES (Site not responding. Last check: 2007-10-15)
		The initial phase will house Takeda's growing headquarters workforce, currently consisting of over 700 employees, as well as the infrastructure for the remaining phases.
		Hines will be responsible for leading the development's design team selection, entitlement effort, master planning, general contractor bidding and oversight of base building and interior construction.
		TPNA was established in 1998 as a wholly-owned subsidiary of Takeda Chemical Industries, Ltd., the largest pharmaceutical company in Japan.
	www.hines.com /hines/PR-2003-08-08.asp (436 words)

Try your search on: Qwika (all wikis)